JP2011200233A5 - - Google Patents

Download PDF

Info

Publication number
JP2011200233A5
JP2011200233A5 JP2011095100A JP2011095100A JP2011200233A5 JP 2011200233 A5 JP2011200233 A5 JP 2011200233A5 JP 2011095100 A JP2011095100 A JP 2011095100A JP 2011095100 A JP2011095100 A JP 2011095100A JP 2011200233 A5 JP2011200233 A5 JP 2011200233A5
Authority
JP
Japan
Prior art keywords
antibody
cytotoxic agent
protein
seq
agent conjugate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011095100A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011200233A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2011200233A publication Critical patent/JP2011200233A/ja
Publication of JP2011200233A5 publication Critical patent/JP2011200233A5/ja
Pending legal-status Critical Current

Links

JP2011095100A 2003-02-10 2011-04-21 膀胱癌及びその他の癌の治療及び検出に有用な名称158p1d7の核酸及び対応タンパク質 Pending JP2011200233A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44663303P 2003-02-10 2003-02-10
US60/446,633 2003-02-10

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2006503486A Division JP2007524361A (ja) 2003-02-10 2004-02-10 膀胱癌及びその他の癌の治療及び検出に有用な名称158p1d7の核酸及び対応タンパク質

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014246948A Division JP2015057068A (ja) 2003-02-10 2014-12-05 膀胱癌及びその他の癌の治療及び検出に有用な名称158p1d7の核酸及び対応タンパク質

Publications (2)

Publication Number Publication Date
JP2011200233A JP2011200233A (ja) 2011-10-13
JP2011200233A5 true JP2011200233A5 (https=) 2012-09-06

Family

ID=32869540

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2006503486A Pending JP2007524361A (ja) 2003-02-10 2004-02-10 膀胱癌及びその他の癌の治療及び検出に有用な名称158p1d7の核酸及び対応タンパク質
JP2011095100A Pending JP2011200233A (ja) 2003-02-10 2011-04-21 膀胱癌及びその他の癌の治療及び検出に有用な名称158p1d7の核酸及び対応タンパク質
JP2014246948A Pending JP2015057068A (ja) 2003-02-10 2014-12-05 膀胱癌及びその他の癌の治療及び検出に有用な名称158p1d7の核酸及び対応タンパク質

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2006503486A Pending JP2007524361A (ja) 2003-02-10 2004-02-10 膀胱癌及びその他の癌の治療及び検出に有用な名称158p1d7の核酸及び対応タンパク質

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014246948A Pending JP2015057068A (ja) 2003-02-10 2014-12-05 膀胱癌及びその他の癌の治療及び検出に有用な名称158p1d7の核酸及び対応タンパク質

Country Status (6)

Country Link
EP (2) EP1594892A2 (https=)
JP (3) JP2007524361A (https=)
AU (3) AU2004210975B2 (https=)
CA (2) CA2515699C (https=)
IL (1) IL170080A (https=)
WO (1) WO2004072263A2 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0501741D0 (en) * 2005-01-27 2005-03-02 Binding Site The Ltd Antibody
EP1840133A1 (en) * 2006-03-29 2007-10-03 Global Biotech Development Corp. Ltd. New immunomodulating oligopeptides
US7718629B2 (en) * 2006-03-31 2010-05-18 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of Eg5 gene
JP2013179911A (ja) * 2012-03-02 2013-09-12 Dainippon Printing Co Ltd 電極付き細胞試験具の接続装置、及びそれを用いた細胞試験装置
EP3494996B1 (en) * 2012-08-23 2026-04-15 Agensys, Inc. Antibody drug conjugates (adc) that bind to 158p1d7 proteins
JP7341060B2 (ja) * 2017-02-10 2023-09-08 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Mapk経路の活性化に関連付けられる癌の処置のための方法及び医薬組成物
WO2023105976A1 (ja) * 2021-12-08 2023-06-15 富士フイルム株式会社 臨床試験支援装置、臨床試験支援装置の作動方法、および臨床試験支援装置の作動プログラム

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US4870009A (en) 1982-11-22 1989-09-26 The Salk Institute For Biological Studies Method of obtaining gene product through the generation of transgenic animals
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4736866B1 (en) 1984-06-22 1988-04-12 Transgenic non-human mammals
US5430136A (en) 1984-10-16 1995-07-04 Chiron Corporation Oligonucleotides having selectably cleavable and/or abasic sites
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5359100A (en) 1987-10-15 1994-10-25 Chiron Corporation Bifunctional blocked phosphoramidites useful in making nucleic acid mutimers
US5124246A (en) 1987-10-15 1992-06-23 Chiron Corporation Nucleic acid multimers and amplified nucleic acid hybridization assays using same
GB8724885D0 (en) 1987-10-23 1987-11-25 Binns M M Fowlpox virus promotors
US5254678A (en) 1987-12-15 1993-10-19 Gene Shears Pty. Limited Ribozymes
CA1340323C (en) 1988-09-20 1999-01-19 Arnold E. Hampel Rna catalyst for cleaving specific rna sequences
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
EP0462145B1 (en) 1989-03-07 1994-04-27 Genentech, Inc. Covalent conjugates of lipid and oligonucleotide
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
WO1991004753A1 (en) 1989-10-02 1991-04-18 Cetus Corporation Conjugates of antisense oligonucleotides and therapeutic uses thereof
ATE157012T1 (de) 1989-11-03 1997-09-15 Univ Vanderbilt Verfahren zur in vivo-verabreichung von funktionsfähigen fremden genen
EP1690934A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5204253A (en) 1990-05-29 1993-04-20 E. I. Du Pont De Nemours And Company Method and apparatus for introducing biological substances into living cells
US5723286A (en) 1990-06-20 1998-03-03 Affymax Technologies N.V. Peptide library and screening systems
ES2264239T3 (es) 1990-06-27 2006-12-16 Princeton University Complejo de proteinas p53/p90'.
SE9002480D0 (sv) 1990-07-23 1990-07-23 Hans Lilja Assay of free and complexed prostate-specific antigen
US5733731A (en) 1991-10-16 1998-03-31 Affymax Technologies N.V. Peptide library and screening method
EP0646178A1 (en) 1992-06-04 1995-04-05 The Regents Of The University Of California expression cassette with regularoty regions functional in the mammmlian host
AU4998993A (en) 1992-08-07 1994-03-03 Epimmune, Inc. Hla binding peptides and their uses
CN1118572A (zh) 1993-03-05 1996-03-13 萨依特尔有限公司 Hla-a2.1组合肽及其用途
CN1127527A (zh) 1993-05-17 1996-07-24 加利福尼亚大学董事会 人免疫缺陷型病毒感染和艾滋病的核酶基因治疗方法
US5837501A (en) 1993-07-09 1998-11-17 Akzo Nobel N.V. Nucleic acid quantitation by co-amplification of target with multiple internal controls
US5804566A (en) 1993-08-26 1998-09-08 The Regents Of The University Of California Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
AU698962B2 (en) 1993-09-14 1998-11-12 Epimmune, Inc. Alteration of immune response using pan DR-binding peptides
US5681697A (en) 1993-12-08 1997-10-28 Chiron Corporation Solution phase nucleic acid sandwich assays having reduced background noise and kits therefor
CH686982A5 (fr) 1993-12-16 1996-08-15 Maurice Stroun Méthode pour le diagnostic de cancers.
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
WO1996002561A1 (en) 1994-07-20 1996-02-01 The General Hospital Corporation Interaction trap systems for detecting protein interactions
US5580731A (en) 1994-08-25 1996-12-03 Chiron Corporation N-4 modified pyrimidine deoxynucleotides and oligonucleotide probes synthesized therewith
US5597909A (en) 1994-08-25 1997-01-28 Chiron Corporation Polynucleotide reagents containing modified deoxyribose moieties, and associated methods of synthesis and use
US5681702A (en) 1994-08-30 1997-10-28 Chiron Corporation Reduction of nonspecific hybridization by using novel base-pairing schemes
US5919652A (en) 1994-11-09 1999-07-06 The Regents Of The University Of California Nucleic acid molecules comprising the prostate specific antigen (PSA) promoter and uses thereof
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US5962428A (en) 1995-03-30 1999-10-05 Apollon, Inc. Compositions and methods for delivery of genetic material
DE69636866D1 (en) 1995-04-11 2007-03-15 Gen Hospital Corp Reverse "two-hybrid"-systeme
US5922687A (en) 1995-05-04 1999-07-13 Board Of Trustees Of The Leland Stanford Junior University Intracellular delivery of nucleic acids using pressure
CU22559A1 (es) 1996-01-17 1999-05-03 Ct Ingenieria Genetica Biotech Sistema de expresión de antígenos heterologos en e. coli como proteínas de fusión
JP2001504799A (ja) 1996-03-11 2001-04-10 エピミューン インコーポレイテッド Hla分子への結合アフィニティーが増加したペプチド
CA2252886C (en) 1996-04-26 2008-02-12 Massachusetts Institute Of Technology Three-hybrid screening assay
EP0960204A4 (en) 1996-07-26 2002-01-23 Sloan Kettering Inst Cancer METHODS AND REAGENTS FOR GENETIC IMMUNIZATION
US5925523A (en) 1996-08-23 1999-07-20 President & Fellows Of Harvard College Intraction trap assay, reagents and uses thereof
ES2290964T3 (es) 1996-10-15 2008-02-16 The Regents Of The University Of California Modelos animales de la evolucion del cancer de prostata humano.
US6365797B1 (en) 1997-10-15 2002-04-02 The Regents Of The University Of California Mice models of human prostate cancer progression
US5846722A (en) 1996-10-16 1998-12-08 Terrapin Technologies, Inc. System to detect small molecule/peptide interaction
US5840501A (en) 1996-10-25 1998-11-24 Bayer Corporation Determination of cPSA
EP1500329B1 (en) 1996-12-03 2012-03-21 Amgen Fremont Inc. Human antibodies that specifically bind human TNF alpha
WO2001081363A1 (en) * 2000-04-27 2001-11-01 Smithkline Beecham Corporation Novel compounds
CA2420543C (en) * 2000-08-22 2013-04-02 Agensys, Inc. Nucleic acid and corresponding protein named 158p1d7 useful in the treatment and detection of bladder and other cancers
JP2004509617A (ja) * 2000-09-08 2004-04-02 シェーリング コーポレイション 哺乳動物遺伝子;関連試薬および方法
WO2002026826A2 (en) * 2000-09-27 2002-04-04 Curagen Corporation Proteins and nucleic acids encoding same
JP2005503760A (ja) * 2001-01-24 2005-02-10 プロテイン デザイン ラブス, インコーポレイテッド 乳癌の診断方法、組成物および乳癌のモジュレーターのスクリーニング方法
EP1576146A2 (en) * 2002-06-03 2005-09-21 Curagen Corporation Therapeutic polypeptides, nucleic acids encoding same, and methods of use
CN104010774B (zh) 2011-09-15 2017-10-13 康富真信息技术股份有限公司 用于自动生成机器人程序的系统和方法

Similar Documents

Publication Publication Date Title
US12162950B2 (en) Antibodies and vaccines for use in treating ROR1 cancers and inhibiting metastasis
JP2018115162A (ja) 新規モジュレータ及びその使用法
JP2011200233A5 (https=)
CN101925612A (zh) 针对癌相关的nfkbib变体的表位的抗体及其用途
RU2015108348A (ru) Антитела, связывающиеся с лизилоксидазоподобным ферментом-2 (loxl2), и способы их применения
US20240317890A1 (en) Her2 single domain antibodies variants and cars thereof
CN111278847B (zh) 分子导向系统肽及其用途
CA2522994A1 (en) Nucleic acids and corresponding proteins entitled 109p1d4 useful in treatment and detection of cancer
CN119421897A (zh) 抗ror1抗体
US11117976B2 (en) Compositions and methods for regulating erythropoiesis
JP5843170B2 (ja) グリオーマの治療方法、グリオーマの検査方法、所望の物質をグリオーマに送達させる方法、及びそれらの方法に用いられる薬剤
TW201111510A (en) Recombinant nucleotide sequence, cell or vector containing the recombinant nucleotide sequence, recombinant single chain anti-polyethylene glycol membrane antibody encoded thereof and method for using the cell containing the recombinant nucleotide sequen
US20240307531A1 (en) Compositions and methods of treating sarcoma lung metastasis
CN107614524B (zh) 治疗
US9581598B2 (en) Diagnosis and treatment of brain tumor
CN103800919A (zh) Tuft1在制备肝癌诊断和治疗制剂中的应用
KR100958943B1 (ko) 쥐알파12/쥐알파13 단백질 기능의 하향 조절제를 포함하는전환성장인자베타 1 (티쥐에프 베타 1) 관련 질병의 예방또는 치료용 약학 조성물
CA2420990A1 (en) Nucleic acid and corresponding protein entitled 85p1b3 useful in treatment and detection of cancer
WO2026077989A1 (en) Isolated tumor antigen-targeting antibody fragments and uses thereof
JP2013147464A (ja) 医薬組成物